{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:35:19Z","timestamp":1790638519686,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["HEROES-AYA"],"award-info":[{"award-number":["HEROES-AYA"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["HEROES-AYA"],"award-info":[{"award-number":["HEROES-AYA"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["HEROES-AYA"],"award-info":[{"award-number":["HEROES-AYA"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["HEROES-AYA"],"award-info":[{"award-number":["HEROES-AYA"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Functional precision oncology (FPO) enables individualized therapy selection using patient-derived tumor models, yet the concordance of distinct ex vivo testing strategies remains unclear. Here, we compare two orthogonal drug sensitivity platforms across molecularly characterized models spanning diverse pediatric (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200913) and adult (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096) cancers. A rapid ATP-based assay quantifies viability within three days, whereas a long-term dynamic image-based platform captures microtumor dynamics over two weeks, incorporating pharmacokinetic features. Up to 50 drugs were profiled across both platforms, with additional combinations evaluated in the long-term assay; genomics-guided targeted drugs served as benchmarks. Both approaches robustly distinguished responders from non-responders and showed strong agreement in therapeutic prioritization (96.5% within 95% limits of agreement). The long-term dynamic platform achieved 81% sensitivity and 78% specificity, while resolving response depth and distinguishing cytostatic from cytotoxic effects. A representative sarcoma case highlights clinical relevance: long-term dynamic profiling predicted disease progression, whereas the short-term assay captured early treatment-associated viability effects. These findings establish cross-platform reproducibility in FPO and provide a systematic benchmarking of such approaches. Defining their complementary utility will be essential for integrating FPO strategies into clinical decision-making.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01555-2","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:25:11Z","timestamp":1781699111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integration and validation of complementary ex vivo assays for functional precision oncology"],"prefix":"10.1038","volume":"10","author":[{"given":"Anna","family":"Loboda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Paluncic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Weidmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Herter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantia","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana P.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"J\u00e1dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Blattner-Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Autry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Frese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Lupar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Imle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Banito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Glimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Peterziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens M.","family":"Kelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia R.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Oehme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"1555_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai, A., Bhola, P. & Welm, A. L. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40, 26\u201335 (2022).","journal-title":"Cancer Cell"},{"key":"1555_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53535-4","volume":"15","author":"R Wegmann","year":"2024","unstructured":"Wegmann, R. et al. Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia. Nat. Commun. 15, 9402 (2024).","journal-title":"Nat. Commun."},{"key":"1555_CR3","doi-asserted-by":"publisher","unstructured":"Bhola, P. D. et al. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Sci. Signalling 13, https:\/\/doi.org\/10.1126\/scisignal.aay1451 (2020).","DOI":"10.1126\/scisignal.aay1451"},{"key":"1555_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-008-0011-3","volume":"9","author":"J Hatok","year":"2009","unstructured":"Hatok, J. et al. In vitro assays for the evaluation of drug resistance in tumor cells. Clin. Exp. Med. 9, 1\u20137 (2009).","journal-title":"Clin. Exp. Med."},{"key":"1555_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/17425255.2019.1554055","volume":"15","author":"G Hamilton","year":"2019","unstructured":"Hamilton, G. & Rath, B. Applicability of tumor spheroids for in vitro chemosensitivity assays. Expert Opin. Drug Metab. Toxicol. 15, 15\u201323 (2019).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1555_CR6","doi-asserted-by":"publisher","unstructured":"Ooft, S. N. et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Transl. Med. 11, https:\/\/doi.org\/10.1126\/scitranslmed.aay2574 (2019).","DOI":"10.1126\/scitranslmed.aay2574"},{"key":"1555_CR7","first-page":"113","volume":"46","author":"RM Sutherland","year":"1971","unstructured":"Sutherland, R. M., McCredie, J. A. & Inch, W. R. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J. Natl. Cancer Inst. 46, 113\u2013120 (1971).","journal-title":"J. Natl. Cancer Inst."},{"key":"1555_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neo.2020.11.005","volume":"23","author":"M Rivera","year":"2021","unstructured":"Rivera, M. et al. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine. Neoplasia 23, 21\u201335 (2021).","journal-title":"Neoplasia"},{"key":"1555_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1177\/24725552211020668","volume":"26","author":"N Choo","year":"2021","unstructured":"Choo, N. et al. High-throughput imaging assay for drug screening of 3D prostate cancer organoids. SLAS Discov. 26, 1107\u20131124 (2021).","journal-title":"SLAS Discov."},{"key":"1555_CR10","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1158\/0008-5472.CAN-22-3702","volume":"83","author":"C Mayoh","year":"2023","unstructured":"Mayoh, C. et al. High-throughput drug screening of primary tumor cells identifies therapeutic strategies for treating children with high-risk cancer. Cancer Res. 83, 2716\u20132732 (2023).","journal-title":"Cancer Res."},{"key":"1555_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00335-y","volume":"6","author":"H Peterziel","year":"2022","unstructured":"Peterziel, H. et al. Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM. NPJ Precis Oncol. 6, 94 (2022).","journal-title":"NPJ Precis Oncol."},{"key":"1555_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth, C. et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 12, 372\u2013387 (2022).","journal-title":"Cancer Discov."},{"key":"1555_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","volume":"30","author":"AM Acanda De La Rocha","year":"2024","unstructured":"Acanda De La Rocha, A. M. et al. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nat. Med 30, 990\u20131000 (2024).","journal-title":"Nat. Med"},{"key":"1555_CR14","doi-asserted-by":"publisher","unstructured":"Acanda De La Rocha, A. M. et al. Clinical utility of functional precision medicine in the management of recurrent\/relapsed childhood rhabdomyosarcoma. JCO Precis Oncol. 5, https:\/\/doi.org\/10.1200\/PO.20.00438 (2021).","DOI":"10.1200\/PO.20.00438"},{"key":"1555_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321\u2013327 (2018).","journal-title":"Nature"},{"key":"1555_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105996","volume":"175","author":"D ElHarouni","year":"2022","unstructured":"ElHarouni, D. et al. iTReX: Interactive exploration of mono- and combination therapy dose response profiling data. Pharm. Res. 175, 105996 (2022).","journal-title":"Pharm. Res."},{"key":"1555_CR17","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1158\/1078-0432.CCR-13-0842","volume":"19","author":"HK Bid","year":"2013","unstructured":"Bid, H. K. et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin. Cancer Res. 19, 6716\u20136729 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1555_CR18","doi-asserted-by":"publisher","unstructured":"Gatzweiler, C. et al. Functional therapeutic target validation using pediatric zebrafish xenograft models. Cancers 14, https:\/\/doi.org\/10.3390\/cancers14030849 (2022).","DOI":"10.3390\/cancers14030849"},{"key":"1555_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/gcc.20198","volume":"43","author":"YP Mosse","year":"2005","unstructured":"Mosse, Y. P. et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 43, 390\u2013403 (2005).","journal-title":"Genes Chromosomes Cancer"},{"key":"1555_CR20","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","volume":"14","author":"JP Koivunen","year":"2008","unstructured":"Koivunen, J. P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275\u20134283 (2008).","journal-title":"Clin. Cancer Res"},{"key":"1555_CR21","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm.4204","volume":"22","author":"International Cancer Genome Consortium PedBrain Tumor","year":"2016","unstructured":"International Cancer Genome Consortium PedBrain Tumor P. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat. Med. 22, 1314\u20131320 (2016).","journal-title":"Nat. Med"},{"key":"1555_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","volume":"137","author":"SM Federico","year":"2020","unstructured":"Federico, S. M. et al. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur. J. Cancer 137, 204\u2013213 (2020).","journal-title":"Eur. J. Cancer"},{"key":"1555_CR23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cncr.33349","volume":"127","author":"R Chugh","year":"2021","unstructured":"Chugh, R. et al. SARC025 arms 1 and 2: a phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer 127, 1301\u20131310 (2021).","journal-title":"Cancer"},{"key":"1555_CR24","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/2159-8290.CD-21-0094","volume":"11","author":"CM van Tilburg","year":"2021","unstructured":"van Tilburg, C. M. et al. The Pediatric Precision Oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov. 11, 2764\u20132779 (2021).","journal-title":"Cancer Discov."},{"key":"1555_CR25","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak, P. et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 11, 2780\u20132795 (2021).","journal-title":"Cancer Discov."},{"key":"1555_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ejca.2022.09.001","volume":"175","author":"KPS Langenberg","year":"2022","unstructured":"Langenberg, K. P. S. et al. Implementation of paediatric precision oncology into clinical practice: the Individualized Therapies for Children with Cancer program \u2018iTHER. Eur. J. Cancer 175, 311\u2013325 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1555_CR27","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","volume":"26","author":"M Wong","year":"2020","unstructured":"Wong, M. et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat. Med. 26, 1742\u20131753 (2020).","journal-title":"Nat. Med."},{"key":"1555_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00865-1","volume":"9","author":"BP Gladstone","year":"2025","unstructured":"Gladstone, B. P. et al. Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps. NPJ Precis Oncol. 9, 96 (2025).","journal-title":"NPJ Precis Oncol."},{"key":"1555_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19\u201334 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1555_CR30","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1158\/2159-8290.CD-23-1194","volume":"13","author":"YR Murciano-Goroff","year":"2023","unstructured":"Murciano-Goroff, Y. R., Suehnholz, S. P., Drilon, A. & Chakravarty, D. Precision oncology: 2023 in review. Cancer Discov. 13, 2525\u20132531 (2023).","journal-title":"Cancer Discov."},{"key":"1555_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.912641","volume":"9","author":"GC Napoli","year":"2022","unstructured":"Napoli, G. C., Figg, W. D. & Chau, C. H. Functional drug screening in the era of precision medicine. Front. Med. 9, 912641 (2022).","journal-title":"Front. Med."},{"key":"1555_CR32","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920\u2013926 (2018).","journal-title":"Science"},{"key":"1555_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386.e310 (2018).","journal-title":"Cell"},{"key":"1555_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","volume":"7","author":"C Pauli","year":"2017","unstructured":"Pauli, C. et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 7, 462\u2013477 (2017).","journal-title":"Cancer Discov."},{"key":"1555_CR35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1080\/15384047.2018.1491498","volume":"19","author":"M Tsoli","year":"2018","unstructured":"Tsoli, M. et al. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer. Cancer Biol. Ther. 19, 1078\u20131087 (2018).","journal-title":"Cancer Biol. Ther."},{"key":"1555_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","volume":"13","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida, G. J. Applications of patient-derived tumor xenograft models and tumor organoids. J. Hematol. Oncol. 13, 4 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1555_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12957-022-02510-8","volume":"20","author":"X Hou","year":"2022","unstructured":"Hou, X. et al. Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells. World J. Surg. Oncol. 20, 37 (2022).","journal-title":"World J. Surg. Oncol."},{"key":"1555_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","volume":"3","author":"KP Guillen","year":"2022","unstructured":"Guillen, K. P. et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat. Cancer 3, 232\u2013250 (2022).","journal-title":"Nat. Cancer"},{"key":"1555_CR39","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114608","volume":"14","author":"LMS Lau","year":"2022","unstructured":"Lau, L. M. S. et al. In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer. Embo Mol. Med. 14, e14608 (2022).","journal-title":"Embo Mol. Med."},{"key":"1555_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct. Target Ther. 8, 160 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1555_CR41","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202318199","volume":"15","author":"C Lago","year":"2023","unstructured":"Lago, C. et al. Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments. Embo Mol. Med. 15, e18199 (2023).","journal-title":"Embo Mol. Med"},{"key":"1555_CR42","doi-asserted-by":"publisher","unstructured":"Schoonbeek, M. C. et al. Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology. NPJ Precis Oncol https:\/\/doi.org\/10.1038\/s41698-025-01266-0 (2026).","DOI":"10.1038\/s41698-025-01266-0"},{"key":"1555_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13046-023-02853-4","volume":"42","author":"J Cartry","year":"2023","unstructured":"Cartry, J. et al. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer. J. Exp. Clin. Cancer Res. 42, 281 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1555_CR44","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1158\/1078-0432.CCR-21-3752","volume":"28","author":"LR Hoes","year":"2022","unstructured":"Hoes, L. R. et al. Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment. Clin. Cancer Res. 28, 1402\u20131411 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1555_CR45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41571-023-00745-2","volume":"20","author":"AWJ van Renterghem","year":"2023","unstructured":"van Renterghem, A. W. J., van de Haar, J. & Voest, E. E. Functional precision oncology using patient-derived assays: bridging genotype and phenotype. Nat. Rev. Clin. Oncol. 20, 305\u2013317 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1555_CR46","doi-asserted-by":"publisher","first-page":"955","DOI":"10.15252\/msb.20177697","volume":"13","author":"J Jabs","year":"2017","unstructured":"Jabs, J. et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol. Syst. Biol. 13, 955 (2017).","journal-title":"Mol. Syst. Biol."},{"key":"1555_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30722-9","volume":"13","author":"J Betge","year":"2022","unstructured":"Betge, J. et al. The drug-induced phenotypic landscape of colorectal cancer organoids. Nat. Commun. 13, 3135 (2022).","journal-title":"Nat. Commun."},{"key":"1555_CR48","doi-asserted-by":"publisher","unstructured":"Paluncic, J. et al. Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumors. bioRxiv, 2026.2002.2018.705724 https:\/\/doi.org\/10.64898\/2026.02.18.705724 (2026).","DOI":"10.64898\/2026.02.18.705724"},{"key":"1555_CR49","doi-asserted-by":"publisher","first-page":"26580","DOI":"10.1073\/pnas.1911273116","volume":"116","author":"E Driehuis","year":"2019","unstructured":"Driehuis, E. et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc. Natl. Acad. Sci. USA 116, 26580\u201326590 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1555_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2011.08.010","volume":"9","author":"SM Dieter","year":"2011","unstructured":"Dieter, S. M. et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9, 357\u2013365 (2011).","journal-title":"Cell Stem Cell"},{"key":"1555_CR51","doi-asserted-by":"publisher","first-page":"918","DOI":"10.15252\/emmm.201607354","volume":"9","author":"CR Ball","year":"2017","unstructured":"Ball, C. R. et al. Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. Embo Mol. Med. 9, 918\u2013932 (2017).","journal-title":"Embo Mol. Med."},{"key":"1555_CR52","doi-asserted-by":"publisher","unstructured":"Zowada, M. K. et al. Functional states in tumor-initiating cell differentiation in human colorectal cancer. Cancers 13, https:\/\/doi.org\/10.3390\/cancers13051097 (2021).","DOI":"10.3390\/cancers13051097"},{"key":"1555_CR53","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.canlet.2015.11.037","volume":"371","author":"TD Dubash","year":"2016","unstructured":"Dubash, T. D. et al. Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Lett. 371, 326\u2013333 (2016).","journal-title":"Cancer Lett."},{"key":"1555_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00828-6","volume":"9","author":"E Crespo","year":"2025","unstructured":"Crespo, E. et al. RevCAR-mediated T-cell response against PD-L1-expressing cells turns suppression into activation. NPJ Precis Oncol. 9, 42 (2025).","journal-title":"NPJ Precis Oncol."},{"key":"1555_CR55","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1128\/MCB.05269-11","volume":"31","author":"B Meder","year":"2011","unstructured":"Meder, B. et al. PINCH proteins regulate cardiac contractility by modulating integrin-linked kinase-protein kinase B signaling. Mol. Cell Biol. 31, 3424\u20133435 (2011).","journal-title":"Mol. Cell Biol."},{"key":"1555_CR56","doi-asserted-by":"publisher","unstructured":"Wrobel, J. K. et al. Rapid in vivo validation of HDAC inhibitor-based treatments in neuroblastoma zebrafish xenografts. Pharmaceuticals 13, https:\/\/doi.org\/10.3390\/ph13110345 (2020).","DOI":"10.3390\/ph13110345"},{"key":"1555_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-0716-2788-4_5","volume":"2589","author":"C Gatzweiler","year":"2023","unstructured":"Gatzweiler, C. et al. Evaluation of antitumor and on-target activity of HDAC inhibitors with the zebrafish embryo xenograft model. Methods Mol. Biol. 2589, 75\u201385 (2023).","journal-title":"Methods Mol. Biol."},{"key":"1555_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/srep19103","volume":"6","author":"M Zanoni","year":"2016","unstructured":"Zanoni, M. et al. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci. Rep. 6, 19103 (2016).","journal-title":"Sci. Rep."},{"key":"1555_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cll.2016.09.002","volume":"37","author":"E Theodorsson","year":"2017","unstructured":"Theodorsson, E. Uncertainty in measurement and total error: tools for coping with diagnostic uncertainty. Clin. Lab Med. 37, 15\u201334 (2017).","journal-title":"Clin. Lab Med"},{"key":"1555_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20603-4","volume":"12","author":"C Koelsche","year":"2021","unstructured":"Koelsche, C. et al. Sarcoma classification by DNA methylation profiling. Nat. Commun. 12, 498 (2021).","journal-title":"Nat. Commun."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01555-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01555-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01555-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:02:15Z","timestamp":1781704935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01555-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01555-2","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported and in direct collaboration with PreComb Therapeutics AG. Micaela Freitas and Jens M. Kelm are both employees of PreComb Therapeutics AG. Ina Oehme and Claudia R Ball received research funding from PreComb Therapeutics. Olaf Witt participated in the advisory boards of Novartis, BMS and Janssen and received research grants from BVD and Day One Therapeutics. I.O. received a research grant from Day One Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}